PMID- 20200692
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20170427
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 46
IP  - 1
DP  - 2010 Jan
TI  - Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid 
      arthritis, psoriatic arthritis and ankylosing spondylitis.
PG  - 13-22
LID - 10.1358/dot.2010.46.1.1444434 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine, has been 
      implicated in the pathology of a variety of chronic autoimmune diseases such as 
      rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The 
      introduction of TNF-alpha inhibitors represented a significant advance in the 
      management of these diseases but the responses of individual patients to 
      TNF-alpha inhibitors are not homogeneous and more therapeutic tools are needed. 
      Golimumab (CNTO-148) is a novel anti-TNF-alpha human monoclonal antibody that 
      blocks both soluble and transmembrane TNF-alpha. It is indicated in the treatment 
      of adults with moderately to severely active rheumatoid arthritis in combination 
      with methotrexate, in adults with active and progressive psoriatic arthritis 
      either alone or in combination with methotrexate, and in adult patients with 
      active ankylosing spondylitis who have had an inadequate response to conventional 
      therapies. Golimumab has generally been well tolerated in clinical trials with a 
      safety profile comparable to other currently available TNF-alpha inhibitors. Its 
      advantages are that it can be administered s.c. once monthly, it is labeled for 
      patient self-administration and is suitable for both s.c. and i.v. 
      administration. Golimumab is currently being investigated in other chronic 
      inflammatory diseases.
CI  - Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
FAU - Campas-Moya, Clara
AU  - Campas-Moya C
AD  - claracampas@gmail.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/adverse effects/pharmacology/*therapeutic use
MH  - Arthritis, Psoriatic/drug therapy/physiopathology
MH  - Arthritis, Rheumatoid/drug therapy/physiopathology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Spondylitis, Ankylosing/drug therapy/physiopathology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
RF  - 60
EDAT- 2010/03/05 06:00
MHDA- 2010/05/14 06:00
CRDT- 2010/03/05 06:00
PHST- 2010/03/05 06:00 [entrez]
PHST- 2010/03/05 06:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
AID - 1444434 [pii]
AID - 10.1358/dot.2010.46.1.1444434 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434.